UroGen Pharma Ltd. (URGN)
| Bid | 9.06 |
| Market Cap | 399.21M |
| Revenue (ttm) | 87.5M |
| Net Income (ttm) | -112.97M |
| EPS (ttm) | -3.02 |
| PE Ratio (ttm) | -3.13 |
| Forward PE | -3.98 |
| Analyst | Buy |
| Ask | 9.58 |
| Volume | 226,366 |
| Avg. Volume (20D) | 372,688 |
| Open | 9.25 |
| Previous Close | 9.29 |
| Day's Range | 9.03 - 9.49 |
| 52-Week Range | 9.03 - 20.70 |
| Beta | 1.09 |
About URGN
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms...
Analyst Forecast
According to 6 analyst ratings, the average rating for URGN stock is "Buy." The 12-month stock price forecast is $31, which is an increase of 227.70% from the latest price.
Next Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago · businesswire.com
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod...
